Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Association of HLA class I type with prevalence and outcome of patients with acute myeloid leukemia and mutated nucleophosmin

K. Kuželová, B. Brodská, J. Schetelig, C. Röllig, Z. Ráčil, JS. Walz, G. Helbig, O. Fuchs, M. Vraná, P. Pecherková, C. Šálek, J. Mayer,

. 2018 ; 13 (12) : e0204290. [pub] 20181217

Jazyk angličtina Země Spojené státy americké

Typ dokumentu klinické zkoušky, časopisecké články, multicentrická studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19027985

Grantová podpora
NV15-25809A MZ0 CEP - Centrální evidence projektů
NV16-30268A MZ0 CEP - Centrální evidence projektů

Acute myeloid leukemia with mutated nucleophosmin (NPMc+ AML) forms a distinct AML subgroup with better prognosis which can potentially be associated with immune response against the mutated nucleophosmin (NPM). As the T-cell-mediated immunity involves antigen presentation on HLA class I molecules, we hypothesized that individuals with suitable HLA type could be less prone to develop NPMc+ AML. We compared HLA class I distribution in NPMc+ AML patient cohort (398 patients from 5 centers) with the HLA allele frequencies of the healthy population and found HLA-A*02, B*07, B*40 and C*07 underrepresented in the NPMc+ AML group. Presence of B*07 or C*07:01 antigen was associated with better survival in patients without concomitant FLT3 internal tandem duplication. Candidate NPM-derived immunopeptides were found for B*40 and B*07 using prediction software tools. Our findings suggest that a T-cell-mediated immune response could actually explain better prognosis of NPMc+ patients and provide a rationale for attempts to explore the importance of immunosuppressive mechanisms in this AML subgroup.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19027985
003      
CZ-PrNML
005      
20231102133746.0
007      
ta
008      
190813s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1371/journal.pone.0204290 $2 doi
035    __
$a (PubMed)30557403
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Kuželová, Kateřina $u Department of Proteomics, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
245    10
$a Association of HLA class I type with prevalence and outcome of patients with acute myeloid leukemia and mutated nucleophosmin / $c K. Kuželová, B. Brodská, J. Schetelig, C. Röllig, Z. Ráčil, JS. Walz, G. Helbig, O. Fuchs, M. Vraná, P. Pecherková, C. Šálek, J. Mayer,
520    9_
$a Acute myeloid leukemia with mutated nucleophosmin (NPMc+ AML) forms a distinct AML subgroup with better prognosis which can potentially be associated with immune response against the mutated nucleophosmin (NPM). As the T-cell-mediated immunity involves antigen presentation on HLA class I molecules, we hypothesized that individuals with suitable HLA type could be less prone to develop NPMc+ AML. We compared HLA class I distribution in NPMc+ AML patient cohort (398 patients from 5 centers) with the HLA allele frequencies of the healthy population and found HLA-A*02, B*07, B*40 and C*07 underrepresented in the NPMc+ AML group. Presence of B*07 or C*07:01 antigen was associated with better survival in patients without concomitant FLT3 internal tandem duplication. Candidate NPM-derived immunopeptides were found for B*40 and B*07 using prediction software tools. Our findings suggest that a T-cell-mediated immune response could actually explain better prognosis of NPMc+ patients and provide a rationale for attempts to explore the importance of immunosuppressive mechanisms in this AML subgroup.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a přežití bez známek nemoci $7 D018572
650    _2
$a ženské pohlaví $7 D005260
650    12
$a MHC antigeny I. třídy $x genetika $x imunologie $7 D015395
650    _2
$a lidé $7 D006801
650    12
$a buněčná imunita $7 D007111
650    12
$a akutní myeloidní leukemie $x genetika $x imunologie $x mortalita $7 D015470
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    12
$a nádorové proteiny $x genetika $x imunologie $7 D009363
650    12
$a jaderné proteiny $x genetika $x imunologie $7 D009687
650    _2
$a prevalence $7 D015995
650    _2
$a míra přežití $7 D015996
650    _2
$a T-lymfocyty $x imunologie $7 D013601
655    _2
$a klinické zkoušky $7 D016430
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Brodská, Barbora $u Department of Proteomics, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
700    1_
$a Schetelig, Johannes $u Department of Internal Medicine I, University Hospital Carl Gustav Carus, Dresden, Germany.
700    1_
$a Röllig, Christoph $u Medical Clinic and Policlinic I, University Hospital Carl Gustav Carus, Dresden, Germany.
700    1_
$a Ráčil, Zdeněk $u Department of Internal Medicine-Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic.
700    1_
$a Walz, Juliane Stickel $u Department of Hematology and Oncology, University of Tuebingen, Tuebingen, Germany.
700    1_
$a Helbig, Grzegorz $u Department of Hematology and Bone Marrow Transplantation, Medical University of Silesia, Katowice, Poland.
700    1_
$a Fuchs, Ota $u Department of Genomics, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
700    1_
$a Vraná, Milena $u HLA department, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
700    1_
$a Pecherková, Pavla, $u Department of Proteomics, Institute of Hematology and Blood Transfusion, Prague, Czech Republic. $d 1980- $7 ctu2013787641
700    1_
$a Šálek, Cyril $u Clinical Department, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
700    1_
$a Mayer, Jiří $u Department of Internal Medicine-Hematology and Oncology, Masaryk University and University Hospital Brno, Brno, Czech Republic.
773    0_
$w MED00180950 $t PloS one $x 1932-6203 $g Roč. 13, č. 12 (2018), s. e0204290
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30557403 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190813 $b ABA008
991    __
$a 20231102133741 $b ABA008
999    __
$a ok $b bmc $g 1433134 $s 1066445
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 13 $c 12 $d e0204290 $e 20181217 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
GRA    __
$a NV15-25809A $p MZ0
GRA    __
$a NV16-30268A $p MZ0
LZP    __
$a Pubmed-20190813

Najít záznam

Citační ukazatele

Možnosti archivace